Observational Study on Patients With Hepatocellular Carcinoma (HCC)

• Conditions: Hepatocellular Carcinoma

• Registration Number: NCT04021056
• Lead Sponsor: Nanfang Hospital, Southern Medical University

Brief Summary

This is an ongoing, longitudinal, single centre, observational, retro-prospective clinical cohort study of patients with HCC in usual clinical practice. All the HCC patients diagnosed and treated in Liver Cancer Center, Nanfang Hospital are consecutively collected and followed up.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-01-01
• Study First Submitted: 2019-04-23
• Status Verified: 2019-07
• Study First Submitted QC: 2019-07-12
• Last Update Submitted: 2019-07-12
• Study First Posted: 2019-07-16
• Last Update Posted: 2019-07-16
• Primary Completion: 2019-08-31
• Study Completion: 2022-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 3000

Inclusion Criteria

• Clinical diagnosis of HCC;
• Age ≥ 16 years;
• Received treatment targeting for HCC at least once, including operation, ablation, TACE, sorafenib, radiotherapy, chemotherapy, etc;
• Good compliance with clinical treatment.

Exclusion Criteria

• Diagnosed as other pathological types such as cholangiocarcinoma, or mixed liver cancer;
• Received only traditional Chinese medicine or symptomatic supportive treatment; (3) survival time ≤ 7 days;
• HCC diagnosed after liver transplantation;
• Poor compliance or important data deficient.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluate the recurrence free survival rate of HCC patients after curative treatments	10 years	In order to identify the potential influence factors of tumor recurrence
Evaluate the overall survival rate of all HCC patients	10 years	In order to identify the potential influence factors of HCC patients survival

Trial Locations

Locations (1)

Nanfang Hospital; 🇨🇳 Guangzhou, Guangdong, China